A Devious Cellular Trick Cancers Can Use to Escape Your Immune System
A researcher discovered that giant cells under a microscope were actually cancer cells hiding inside other cancer cells. (Source: NYT Health)
Source: NYT Health - September 29, 2022 Category: Consumer Health News Authors: Gina Kolata Tags: Cancer Immune System Research Immunotherapy eLife (Journal) your-feed-science your-feed-health Source Type: news

Immunotherapy in Non-Melanoma Skin Cancers: Future Opportunities and Directions Immunotherapy in Non-Melanoma Skin Cancers: Future Opportunities and Directions
Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2022 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news

Managing Immunotherapy Side Effects in Patients With Non-Melanoma Skin Cancers: What You Need to Know Managing Immunotherapy Side Effects in Patients With Non-Melanoma Skin Cancers: What You Need to Know
Medscape Medical Affairs (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2022 Category: Consumer Health News Tags: None Virtual Symposium Source Type: news

Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination
(MedPage Today) -- First-line immunotherapy for BRAF-positive melanoma, followed by targeted therapy at progression, led to a "clinically meaningful" survival benefit, a randomized trial showed. Combination immunotherapy with nivolumab (Opdivo... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - September 29, 2022 Category: Dermatology Source Type: news

Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC Neoadjuvant Immunotherapy Shows Promise for Resectable CSCC
Some patients develop more advanced cancer that requires surgery, often on exposed surfaces like the scalp, face, or neck.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Allergists Seek to Improve Shot, Sublingual-Tablet Adherence Allergists Seek to Improve Shot, Sublingual-Tablet Adherence
A review of published studies lists reasons why patients don ' t stick with allergy shots and sublingual immunotherapy, highlighting the need for careful consultation in choosing these treatments.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 26, 2022 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
IMT-009 Phase 1/2a clinical trial initiation expected in Q4 2022 Preclinical data indicate that IMT-009 restores tumor killing activity with potential for use as monotherapy or in combination with existing therapeutics WALTHAM, Mass., Sept. 21, 2022 ... Biopharmaceuticals, Oncology, FDA Immunitas Therapeutics, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 21, 2022 Category: Pharmaceuticals Source Type: news

Immunotherapy Treats Fibrosis in Mice
Researchers report that vaccination against proteins found on profibrotic cells reduced liver and lung fibrosis in laboratory rodents. (Source: The Scientist)
Source: The Scientist - September 16, 2022 Category: Science Tags: News & Opinion Source Type: news

New Treatment Approach Boosts Odds Against 2 Types of Skin Cancer
THURSDAY, Sept. 15, 2022 -- Skin cancer patients appear to fare better if they receive immunotherapy before their cancers are surgically removed, a pair of clinical trials show. In fact, some do so well that their immune system essentially... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 15, 2022 Category: General Medicine Source Type: news

Episode 3: Immunotherapy and Lung Cancer Treatment Episode 3: Immunotherapy and Lung Cancer Treatment
Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2022 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer
(MedPage Today) -- PARIS -- Nearly two-thirds of patients with untreated cisplatin-ineligible advanced urothelial cancer responded to an antibody-drug conjugate (ADC) and immunotherapy, a small randomized study showed. Overall, 49 of 76 patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 14, 2022 Category: Hematology Source Type: news

‘Glass bubble’ nanocarrier boosts effects of combination therapy for pancreatic cancer
Key takeaways:Improving drug delivery. Custom-designed nanoparticles that deliver drugs directly to tumors can avoid the toxicity of traditional chemotherapy.Crafting a ‘combo’ carrier. Researchers designed an innovative nanoparticle outfitted with both a chemotherapy drug and an immune system –boosting drug.Two are better. The two-drug nanocarrier was significantly better at shrinking pancreatic tumors and preventing metastasis than nanocarriers that delivered the drugs individually.Over the past 30 years, progress in early detection and treatment of cancer has helped reduce the overall death rate by more than 30%. ...
Source: UCLA Newsroom: Health Sciences - September 13, 2022 Category: Universities & Medical Training Source Type: news

Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma
(MedPage Today) -- PARIS -- The randomized trial data have spoken, and they favor neoadjuvant immunotherapy over adjuvant treatment for resectable melanoma. Neoadjuvant pembrolizumab (Keytruda) followed by surgery and additional pembrolizumab... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2022 Category: Hematology Source Type: news

Survival Bump in Unfit NSCLC With First-Line Immunotherapy
(MedPage Today) -- PARIS -- Treatment with a PD-L1 inhibitor held a survival advantage over single-agent chemotherapy for unfit non-small cell lung cancer (NSCLC) patients ineligible for platinum doublets, findings from the IPSOS trial showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2022 Category: Hematology Source Type: news

Could Nivolumab Prevent Oral Cancer in High-Risk Patients? Could Nivolumab Prevent Oral Cancer in High-Risk Patients?
Giving the immunotherapy nivolumab to patients with oral proliferative leukoplakia not only reduces lesions but also may prevent cancer progression, suggests the first study in the preventive setting.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 13, 2022 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news